Bausch Health Companies Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Bausch Health Companies Inc. (BHC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2017-03-01
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2015 was $1.01B, a 661.69% increase from fiscal 2014.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2014 was $132.60M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month as first filed |
|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-01 | |
| 2015-12-31 | $1.01B 10-K · filed 2017-03-01 | $1.01B 10-K · filed 2016-04-29 |
| 2014-12-31 | $132.60M 10-K · filed 2016-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |